Monovisc Shortage Update: What Patients Need to Know in 2026

Patients across the country are searching for clarity: Is Monovisc in shortage? Why is it so hard to get? Will it ever be easier to find? This article gives you a clear, honest answer to those questions in 2026 — so you can stop worrying about rumors and start focusing on getting your treatment.

Current Monovisc Shortage Status (2026)

As of 2026, there is no active FDA-declared shortage of Monovisc. Monovisc is manufactured by Anika Therapeutics at their Bedford, Massachusetts facility and distributed in the U.S. by DePuy Synthes (a Johnson & Johnson company). Both companies have not reported any manufacturing disruptions or supply chain issues that would constitute a formal shortage.

However — and this is critical — "no official shortage" doesn't mean "easy to find." Patients routinely report difficulty locating Monovisc, and that difficulty is real. It just has structural causes rather than being driven by manufacturing or supply problems.

Why Patients Still Struggle to Find Monovisc Despite No Formal Shortage

Several structural factors make Monovisc feel like it's in shortage even when it isn't:

Specialty distribution: Monovisc moves through medical supply channels — not retail pharmacy networks. Your doctor's office must order it specifically, meaning availability depends on what individual providers stock.

Non-preferred insurance status: Aetna, BCBS, and many commercial plans classify Monovisc as non-preferred, steering prescribers and patients toward competitors like Durolane and Synvisc-One instead. This reduces the number of offices that actively stock Monovisc.

Prior authorization delays: Commercial insurance typically requires 5–15 business days to process a prior authorization for Monovisc. During that time, patients are in limbo — unable to get the product even if their provider has it.

High cost without coverage: At $1,521–$2,047 per syringe without insurance, many patients simply cannot access Monovisc if their coverage is denied or if they have a high deductible.

Has Monovisc Ever Been in Official Shortage?

Monovisc has not appeared on the FDA's official drug shortage database. It is classified as a Class III medical device (PMA P090031) rather than a traditional pharmaceutical drug, which means it is tracked differently from medications like GLP-1 agonists or ADHD drugs that have made headline shortages in recent years.

That said, access to viscosupplements generally — including Monovisc — has tightened in recent years as more commercial insurers moved to non-preferred status for specific brands. This isn't a shortage in the traditional sense, but it has had a real impact on patient access.

What the "No Shortage" Designation Means for Patients in Practice

If there's no formal shortage, then Monovisc is available — you just need to find the right source. Here's what that means practically:

Monovisc is being manufactured and shipped to providers across the country right now.

If your current provider doesn't have it, other providers near you likely do — you just need to identify them.

Your provider can order Monovisc from specialty distributors within a few business days if they don't currently stock it but are willing to do so.

The barriers to access are largely administrative (prior auth, insurance status) rather than supply-related — and they can often be navigated with the right preparation.

What to Do Right Now If You Can't Find Monovisc

Verify your insurance coverage. Call your plan's member services and confirm whether Monovisc is covered, what the PA requirements are, and whether any preferred alternatives are available without PA.

Use medfinder to locate stocking providers. medfinder contacts providers near you to find who has Monovisc in stock and can fill your prescription, then texts you the results.

Start the PA process early. If your provider submits the prior authorization request the same day they prescribe Monovisc, you may have approval in hand by the time your injection appointment arrives.

Consider a bridge treatment. If you're in pain right now while waiting for Monovisc approval or access, a corticosteroid injection can provide faster (though shorter-term) relief.

Explore alternatives. Synvisc-One, Durolane, and Euflexxa are clinically comparable and may be more readily available and better covered depending on your plan.

Will Monovisc Access Get Better or Worse in 2026?

The landscape for viscosupplement coverage continues to evolve. Some insurers are expanding coverage while others are tightening formularies or removing certain HA products from covered benefits entirely. Without a generic equivalent to Monovisc on the market in 2026, cost is unlikely to decrease significantly in the near term. The most reliable path to access remains working with your provider and insurance to navigate the system — and using tools like medfinder to find stocking locations near you.

Visit medfinder to start finding providers near you, or read our provider-focused shortage guide for a deeper look at why insurance formulary changes are the biggest access factor in 2026.